Xenon Pharmaceuticals Inc (XENE)

$43.15

+0.7

(+1.65%)▲

Market is closed - opens 8 PM, 29 Nov 2024

Performance

  • $42.07
    $43.41
    $43.15
    downward going graph

    2.5%

    Downside

    Day's Volatility :3.08%

    Upside

    0.59%

    downward going graph
  • $33.62
    $50.99
    $43.15
    downward going graph

    22.09%

    Downside

    52 Weeks Volatility :34.07%

    Upside

    15.38%

    downward going graph

Returns

PeriodXenon Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
3.71%
-6.1%
0.0%
6 Months
9.95%
1.2%
0.0%
1 Year
24.41%
12.2%
0.0%
3 Years
58.45%
10.8%
-21.2%

Highlights

Market Capitalization
3.2B
Book Value
$12.31
Earnings Per Share (EPS)
-2.81
PEG Ratio
-0.06
Wall Street Target Price
57.183
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-18.92%
Return On Equity TTM
-26.71%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-96.3M
EBITDA
-233.7M
Diluted Eps TTM
-2.81
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-3.08
EPS Estimate Next Year
-3.5
EPS Estimate Current Quarter
-0.81
EPS Estimate Next Quarter
-0.85

Analyst Recommendation

Buy
    95%Buy
    4%Hold
    0
    0%Sell
Based on 24 Wall street analysts offering stock ratings for Xenon Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 24 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
23
23
23
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 32.52%

Current $43.15
Target $57.18

Technicals Summary

Sell

Neutral

Buy

Xenon Pharmaceuticals Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
1.7%
9.95%
24.41%
58.45%
269.45%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.91%
-22.62%
-5.64%
15.07%
102.66%
Biontech Se
Biontech Se
4.66%
25.97%
22.38%
-67.3%
441.77%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-11.7%
68.83%
59.14%
40.17%
115.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-1.95%
4.52%
33.38%
145.68%
112.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
NA
NA
-0.06
-3.08
-0.27
-0.19
NA
12.31
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.25
18.25
1.1
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc
Buy
$3.2B
269.45%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.1B
102.66%
18.25
33.61%
Biontech Se
Biontech Se
Buy
$27.1B
441.77%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$31.6B
115.51%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$118.9B
112.25%
32.84
-4.51%

Insights on Xenon Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 8.76K → 5.38M (in $), with an average increase of 99.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 4 quarters, -44.74M → -62.79M (in $), with an average decrease of 12.1% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.1% return, outperforming this stock by 34.7%

Institutional Holdings

  • FMR Inc

    9.13%

  • venBio Select Advisor LLC

    7.48%

  • Driehaus Capital Management LLC

    5.83%

  • Wellington Management Company LLP

    5.05%

  • BRAIDWELL LP

    3.57%

  • COMMODORE CAPITAL LP

    3.56%

Corporate Announcements

  • Xenon Pharmaceuticals Inc Earnings

    Xenon Pharmaceuticals Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

xenon® (nasdaq: xene) is a biopharmaceutical company focused on the development of novel medicines through the application of our proprietary discovery platform, which we refer to as extreme genetics. our product candidates are based on genetic insights derived from our research of families where individuals exhibit severe traits, or phenotypes. we apply our expertise to predict which phenotypes are caused by single-gene defects. by identifying and characterizing the single-gene defects responsible for such severe phenotypes, we gain valuable insights into their function in human biology and their potential as drug targets. given that these targets are often involved in diseases beyond the rare genetic disorders in which they are first identified, we are developing proprietary product candidates to treat both orphan as well as more prevalent diseases.

Organization
Xenon Pharmaceuticals Inc
Employees
251
CEO
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.
Industry
Health Technology

FAQs